Press Release

Hoffmann La Roche Diagnostics Limited Dominated the Market for Europe POCT Device Market in 2016

Europe POCT Device Market is expected to reach USD 11.68bin 2016, at a CAGR of 8.6% in the forecast period 2017 to 2024. The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024. Blood Glucose testing kits market has the largest market segment in Euope POCT device market.Europe POCT Device MarketVisit full Report@

The Europe POCT Device Market is highly concentrated to a few big players and rest to local players who cater to domestic markets only. Roche dominated the Euope POCT device market market accounting for the highest market share in 2016, followed by Siemens and Abbott. Other players in this market include Alere Inc., Becton, Dickinson and Company, Johnson & Johnson Services Inc., PTS Diagnostics, Instrumentation Laboratory, Nova Biomedical, Beckman Coulter, Inc. among others holds 41.1% of the Europe POCT device market in 2016.

Roche Diagnostics Limited : 

Founded in 1896 as F. Hoffmann La , a diagnostic division of Hoffmann-La Roche and head quartered in Basel, Switzerlandis focused on oncology, immunology, ophthalmology, infectious diseases, and neuroscience. The company operates through two business segments: Pharmaceuticals and Diagnostics.

Recent Developments:

  1. In August 2016, Roche Diagnostics Ltd., received FDA approval for cobas Influenza A/B & RSV test for the cobasLiat System that differentiates flu and Respiratory Syncytial Virus (RSV) in 20 minutes.
  2. In May 2015, Roche Diagnostics Ltd., received FDA CLIA Waiver for the cobasLiat PCR System and Strep A assay to test Strep A in throat swab specimen.

 Siemens AG:

Incorporated in 1847 and headquartered in Munich, Germany specializing in supplier of systems for power generation and transmission, medical diagnosis, infrastructure and industry solutions. Its main focus is on electrification, automation and digitalization. Siemens AG operates in more than 200 countries across United States, Europe, Western Hemisphere, Africa, and Asia-Pacific SA/NV, Beersel (Belgium), ETM professional control GmbH, Eisenstadt (Austria), Siemens Healthcare Diagnostics Products GmbH (Marburg), Linacre Investments (Pty) Ltd., Kenilworth (South Africa), Siemens Healthcare FZ LLC (Dubai).

Recent Developments:

  1. In November, 2016, Siemens strengthened its healthcare business through public listing to give more focus and flexibility in pursuing its growth strategy.
  2. In June, 2016, Siemens opened a new headquarter in Munich to enhance its global presence in this market.


Founded in 1888 and headquartered in Lake Bluff, Illinois, U.S., Abbott manufactures pharmaceuticals, molecular diagnostics, diabetes care nutritionals, and vascular. The company focused on development and marketing of diagnostics products, medical devices, nutrition and branded generic pharmaceuticals.

Recent Developments:

  1. In May, 2017, Abbott announced CE Mark approval and its use of the new Rx Insertable Cardiac Monitor (ICM), which is the world's first smartphone compatible ICM to identify or detect cardiac arrhythmias, including atrial fibrillation (AF), for therapy.
  2. In May, 2017, Abbott announced the national reimbursement for freestyle Libre in France, providing access to revolutionary technology for people suffering with diabetes. This would help thousands of people to have access to test type 1 and type 2 diabetes.

Client Testimonials